Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest outcomes, and is associated with a high risk of relapse and metastasis. The treatment choices for this malignancy have been confined to conventional ...

Apr 25, 2021 · Some studies have shown that CDH3 is overexpressed in TNBC to an extent of over 50%, which is markedly correlated with poor OS, 17,18 and associated with the promotion of key cancer features like augmented cell migration, invasion, and tumorigenic and metastatic ability in BC models. 19,20 A recent study revealed a strong association between ...

May 8, 2024 · Tumor-infiltrating lymphocytes (TIL) are found most extensively in triple-negative breast cancer (TNBC) compared with other breast tumor subtypes . The penetration of CD8 + T cells into the tumor nests of TNBC, beyond their accumulation in the outer stroma, correlates positively with improved patient survival outcomes [ 11 ].

Jul 1, 2021 · PCA062 is a P-cadherin specific antibody–drug conjugate that utilizes the clinically validated SMCC-DM1 linker payload to mediate potent cytotoxicity in cell lines expressing high levels of P-cadherin in vitro, while displaying no specific activity in P-cadherin–negative cell lines.

STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim.

Our results suggest the existence of molecular networks in TNBC, characterized by explicit alterations in the cell cycle, DNA repair, nucleotide synthesis, metabolic pathways, NF-κB signaling, inflammatory response, and angiogenesis.

Cdh3 controls leader cell protrusion dynamics through local production of laminin, which is required for integrin/focal adhesion function. Our findings highlight how a subset of leader cells interact with the microenvironment to direct collective migration.

Jan 1, 2022 · In fact, human epidermal growth factor receptor 2 (HER2)–positive and triple-negative breast cancer (TNBC) show a higher mutational burden than hormone receptor (HR)–positive BC [5, 6].

Using breast TNBC models, we demonstrated, for the first time, that P-cadherin co-localizes with E-cadherin, promoting cell invasion due to the disruption caused in the interaction between E-cadherin and cytoplasmic catenins.

Mar 14, 2017 · In this study, by analyzing The Cancer Genome Atlas (TCGA) provisional datasets and several small-size breast datasets, we found that cadherins (CDHs) 2, 4, 6, and 17 were frequently amplified/overexpressed in 47% of TNBC while E-cadherin (CDH1) was downregulated/mutated at 10%.